Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease: Pitfalls and Promise

Research output: Contribution to journalArticle


The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10. More recently CCR6 and its ligand CCL20 have also received attention; the expression of the latter in enterocytes being manipulated through Smad7 signalling. These pathways, selected based on their fundamental role in regulating mucosal immunity have led to the development of several therapeutic candidates that have been tested in early phase clinical trials with variable clinical efficacy. In this article, we appraise the status of chemokine-directed therapy in IBD, review recent developments and nominate future areas for therapeutic focus.


Original languageEnglish
Pages (from-to)S641–S652
JournalJournal of Crohn's & Colitis
Issue numbersuppl_2
Early online date23 Feb 2018
Publication statusPublished - 22 Aug 2018


  • Eldelumab, Mongersen, Vercirnon

ASJC Scopus subject areas